Association of cytochrome P450 2C19 polymorphisms with coronary heart disease risk
A protocol for systematic review and meta analysis

Yongxin Yang, MMa,∗, Yaping Zhang, MBa, Ming Ren, MMb, Yonglan Wang, MBa, Zhuoma Cairang, MBa, Rongxiang Lin, MMa, Haixia Sun, MMc, Jianju Liu, MBa

Abstract
Background: Polymorphisms in the cytochrome P450 2C19 (CYP2C19) gene have been reported to be associated with coronary heart disease (CHD), but the results were not consistently analyzed among different patient groups. To derive a more precise estimation of these associations, we will conduct a meta-analysis to investigate the polymorphisms of CYP2C19 in all published studies.

Methods: Electronic databases (Google Scholar, ISI Web of Science, Pubmed, Embase, China National Knowledge Infrastructure, Wanfang, and China Biological Medicine) will be used to search clinical case-control or cohort studies about CYP2C19 polymorphism and CHD published until November 2020. Two reviewers will independently select the study, extract the data, and evaluate the quality of the study. Odds ratios with 95% confidence interval will be used to evaluate the strength of the association between the CYP2C19 polymorphism and CHD susceptibility under 4 genetic models. Subgroup analysis will be conducted by different ethnicity and genotyping method. Sensitivity analysis will be performed via sequentially omitting each of the included studies 1 at a time. Begg funnel plots and Egger test will be used to examine the potential publication bias. All the statistical analyses will be performed using Review Manager 5.3 and Stata 12.0.

Results: This study will provide a better understanding of the association between CYP2C19 polymorphisms and coronary heart disease risk.

Conclusion: The publication of this protocol will minimize the possibility of bias due to post hoc changes to the analysis protocol, thus helping to obtain reliable evidence.

OSF registration number: DOI 10.17605/OSF.IO/R7U93

Abbreviations: CHD = coronary heart disease, CI = confidence interval, CYP2C19 = polymorphisms in the cytochrome P450 2C19, HWE = Hardy–Weinberg equilibrium, NOS = Newcastle–Ottawa scale, OR = odds ratio.

Keywords: coronary heart disease, meta-analysis, polymorphism, polymorphisms in the cytochrome P450 2C19

1. Introduction

Coronary heart disease (CHD) is one of the most common cardiovascular diseases in the world, which is characterized by arteriosclerosis and coronary artery stenosis and even obstruction. The incidence and mortality of CHD have been showing a downward trend since the 1970s, mainly due to the improvement of prevention and treatment measures and the reduction of major risk factors.1,2 However, the disease is still being the main cause of death and disability among people aged 35 and older, and seriously endangers human health.3–5 In particular, individuals with acute myocardial infarction have a higher risk of recurring CHD events, recurring myocardial infarction, and death.6 It is estimated that more than 9.4 million people worldwide died of ischaemic heart disease in 2016.7 In China, the mortality rate of CHD in urban residents was 115.32/100,000, and that in rural residents was 122.04/100,000.8 Whether in developed or developing countries, the management of CHD every year is related to huge long-term medical expenses.9

The complex pathophysiology of CHD depends on a large number of lifestyle and environmental risk factors of its
association studies. In addition, genome-wide association studies polymorphism and CHD susceptibility. It is necessary to conduct a meta-analysis of all eligible studies to analyze among different patient groups. Therefore, it is more convincing evidence on the association of CYP2C19, which may be involved in the occurrence and development of CHD. Twin studies showed that the heritability of CHD is estimated to be between 41% and 77%. More recently, researchers have proposed genetic risk factors for CHD, which can be identified by the robust genome-wide association studies. In addition, genome-wide association studies showed that there are numerous candidate genes and considerable single nucleotide polymorphisms remarkably associated with CHD, such as VEGF, SCARB1, ADAMTS-7, SCARB1, VEGFA, MADD-FOLH1, CYP3A and APOC3.

Cytochrome P450 2C19 (CYP2C19), as one of the main cytochromes P450s drug metabolic enzymes in human body, is encoded by chromosome 10 and expressed in the human liver. It is the most polymorphic member of CYP2C subfamily. CYP2C19 gene mutation can change the activity of human related enzymes, affect the metabolic process of related drugs, and lead to cardiovascular events in patients with CHD. For example, the Allelic variation classified the population according to the catalytic activity of CYP2C19 to ultra-rapid, extensive and poor phenotypes for drug clearance. CYP2C19 gene polymorphism has been proved to be a compelling predictor of clopidogrel resistance, which can lead to failure in the treatment of CHD. Patients with loss-of-function allelic variants (CYP2C19 * 2 and CYP2C19 * 3) are more prone to thromboembolic events. In Zhang’s study, the adverse impact of CYP2C19*2 polymorphisms was found not only in the risk of CHD, but also in the adverse clinical outcomes in CHD patients during a long follow-up period. Ercan reported that among Turkish people, smokers with CYP2C19*2 mutations have a 3.7 times risk of CHD. The CYP2C19 * 3 genotype was found to be significantly more common in Chinese Uighur populations with CHD.

On the basis of this information, these studies have suggested that the single-nucleotide polymorphism in the CYP2C19 gene may be involved in the occurrence and development of CHD. Unfortunately, the results of these studies were not consistently analyzed among different patient groups. Therefore, it is necessary to conduct a meta-analysis of all eligible studies to obtain more convincing evidence on the association of CYP2C19 polymorphism and CHD susceptibility.

2. Methods/design

2.1. Study registration

The retrospective review does not involve the evaluation of patients’ personal information or rights, so ethical approval is not required. It cannot be ignored that we have registered the protocol in the Open Science Framework (OSF) in advance, and the registration number is DOI 10.17605/OSF.IO/R7O9J. In addition, this systematic review and meta-analysis will be reported in accordance with the preferred reporting items for systematic reviews and meta-analysis protocols 2015.

2.2. Inclusion criteria

The inclusion criteria will be made based on the PICOS principle (participants, intervention, control, outcome, and study type):

1. Types of studies: all case-control studies or cohort studies that evaluated the association between CYP2C19 polymorphisms and CHD risk will be incorporated in our review. No restriction will be put on the publication date of the studies.
2. Types of participants: the present meta-analysis will include subjects with CHD, and the diagnosis should be made in accordance with well-established guidelines. The control subjects should be defined as healthy individuals. Regardless of age, gender, or country.
3. Studies that presented original data, or provided the genotypic frequency of both case and control samples or had odds ratios (ORs) with 95% confidence interval (CI) values.
4. Primary outcome: the association between CYP2C19 polymorphisms and risk of CHD.

2.3. Exclusion criteria

Studies will be excluded from the meta-analysis according to the following criteria:

1. review articles,
2. in vitro or animal study,
3. case reports,
4. conference abstracts,
5. Newcastle–Ottawa scale (NOS) score is less than 6,
6. studies that did not provide allele frequencies or genotypic for samples,
7. studies on the relationship between CYP2C19 gene polymorphism and non-coronary heart disease,
8. overlapping or duplicate studies.

2.4. Search strategy

Several online databases including Pubmed, ISI Web of Science, Embase, Google Scholar, Wanfang, China Biological Medicine, and China National Knowledge Infrastructure will be searched up to November, 2020. Medical subject headings (MeSH) and synonymous free texts will be combined to improve the comprehensiveness and sensitivity of literature retrieval. The language will be restricted to Chinese and English. The following keywords will be used: (“coronary heart disease” OR “CHD” OR “coronary artery disease” OR “CAD”) and (“Cytochrome P-450 CYP2C19” OR “CYP2C19”) and (“polymorphism” OR “variant” OR “genotype” OR “mutation”). The search strategy for PubMed is shown in Table 1, and the corresponding keywords will be used in the Chinese databases. In addition, we will supplement this search by manually scanning the cross-references of related articles.

2.5. Data collection and analysis

2.5.1. Selection of studies. The researchers of our team have received professional training on the purpose and process of the review in advance. Two reviewers (Yongxin Yang and Yaping Zhang) will perform the selection process independently, with cases of disagreement will be resolved by adjudication by a third reviewer (Ming Ren). The screening process of the article includes
reading the title first, then the abstract and the full text to determine whether it meets the inclusion criteria. The researchers will record the reasons for excluding each study in light of the preferred reporting items for systematic reviews and meta-analysis guidelines and report the screening results.[31] The flowchart is shown in Figure 1.

2.5.2. Data extraction. Each publication will be evaluated thoroughly, and data will be extracted independently by 3 researchers, including year of publication, surname of the first author, ethnicity of each study population, country, mean age, gender, numbers of subjects, genotyping methods, allele frequencies and genotype distribution of CYP2C19 polymorphisms. Group discussions will be conducted to resolve any disagreements in the extraction process. If the data for a paper is incomplete or unconvincing, we will try to contact the author via email. In addition, the Hardy–Weinberg equilibrium (HWE) of genotype distributions in the control group will also be examined.

2.5.3. Study quality assessment. Two reviewers (Yonglan Wang and Zhuoma Cairang) will independently assess the quality of all included studies based on NOS, which is specifically used to assess the quality of observational studies.[32] When they encounter disagreement, they will resolve these issues with the help of a third member (Rongxiang Lin). As we all know, the NOS values arrange from 0 to 9. The quality of publication below 6 stars is low, and the quality of research above 6 stars is high. Only studies with more than 6 stars will be included in our study.

2.5.4. Statistical analysis. The ORs with their corresponding 95% CIs will be used to assess the strength of the association between CYP2C19 polymorphisms and CHD susceptibility. The pooled ORs will be conducted for 4 genetic (allelic genetic model: T versus C; recessive genetic model: TT versus CT + CC; dominant genetic model: TT + CT versus CC; and additive model: TT versus CC. “T” and “C” represent the mutant allele and the wild-type allele, respectively). Then the most reasonable genetic model of inheritance will be identified based on the relationships between the 4 pairwise comparisons. After identifying the potential genetic model, the genotype count will be collapsed into 2 categories to obtain a combined result. The significance of the pooled ORs will be determined by Z-test, with $P < .05$ considered statistically significant. In addition, the Fisher exact test will be used to assess the deviation of CYP2C19 polymorphism frequency from the expected values under the HWE among healthy controls. When $P < .05$, the study is considered to be inconsistent with HWE. $x^2$ test-based Q statistic and $I^2$ will be applied to assess the overall heterogeneities. If $I^2$ values $< 50\%$ and $P > .05$, heterogeneity is deemed to be low, and a fixed-effect model will be selected for data integration. Otherwise, a random-effect model will be used.[33,34] In our study, all statistical analyses will be conducted by using Stata version 12.0 (Stata Corporation, College Station, TX) and Review Manager 5.3 (Cochrane Collaboration, Oxford, UK).

2.5.5. Assessment of heterogeneity. If there is obvious heterogeneity among studies, we will conduct the meta-regression analysis, subgroup analysis or sensitivity analysis to explore the potential sources of heterogeneity. The confounding factors include ethnicity, year of publication, type of study, total sample size, and RR (ratio of case size to control size).

2.5.6. Subgroup analysis. Subgroup analysis will be conducted by different ethnicity, genotyping method, total sample size and deviation from HWE, and so on.

2.5.7. Sensitivity analysis. The sensitivity analysis will be carried out by sequentially omitting each of the included studies 1 at a time to measure the reliability and robustness of the research results.

2.5.8. Assessment of publication biases. Funnel plots will be used to evaluate publication bias if more than 10 eligible studies are included, and the criterion was whether the funnel plot is symmetric or not. If the funnel chart is asymmetric, there may be publication bias. What’s more, Begg rank correlation test and Egger test will also be used for checking the potential publication bias, and a $P$-value smaller than .05 is considered statistically significant.

2.5.9. Grading the evidence quality. GRADE method will be used to assess the quality of evidence for our findings.[35] The quality of evidence can be divided into 4 levels: high, medium, low, and very low quality. Researchers should consider certain factors that may reduce the quality of the evidence, such as the heterogeneity between groups, estimate precision of effect, publication bias, and evidence directness. Moreover, large
magnitude effect and dose-response gradient that increase the quality of evidence should also be given enough attention.

3. Discussion

Cardiovascular disease is the largest cause of death in the world, especially CHD manifested by angina pectoris or myocardial infarction. Although the mortality rate of CHD has declined, it still causes one-third of all deaths over the age of 35 in the past few decades.[36] The disease is regarded as a complex multifactorial disease caused by the interaction between multiple environmental and genetic factors.[37] Traditional risk factors are considered to be the cause of most CHDs, although 15% to 20% of patients have no identified risk factors, making it impossible to prevent adverse cardiovascular events with adequate treatment. Early identification and intervention strategies are essential to reduce the incidence and mortality of CHD in high-risk population. Identifying the genetic components of the disease is the important area in cardiovascular disease research, because clarifying the genes related to CHD will affect all efforts towards understanding of the mechanism level, its prevention and treatment. Fortunately, genome-wide association studies have confirmed some genes related to the susceptibility to CHD in different populations around the world, of which the CYP2C19 gene is well known.

So far, although many researchers have focused on the relationship between CYP2C19 gene polymorphism and CHD susceptibility, there has been no systematic assessment of the cumulative evidence for this association. In this study, we will conduct a systematic review and meta-analysis to combine results from numerous studies and generate a more reliable estimate of risk association to provide guidance for the prevention and treatment of coronary heart disease. The strengths of this study include the following aspects:

(1) large datasets from all recent eligible studies will be incorporated;
(2) for the exploration of heterogeneity, we will try to avoid post-group subgroup analysis; and

---

Figure 1. Flow chart of study selection.
sensitivity analysis of each genetic model will be performed to improve the reliability of the results. Therefore, publishing the protocol will avoid the potential bias related to data mining as much as possible and will help to obtain convincing evidence.

Author contributions

Conceptualization: Yongxin Yang, Yaping Zhang.
Investigation: Ming Ren, Yonglan Wang.
Supervision: Yongxin Yang.
Writing — original draft: Zhumaa Cairang, Rongxiang Lin.
Writing — review & editing: Haixia Sun, Jianju Liu.

References

[1] Mensah GA, Wei GS, Sorlie PD, et al. Decline in cardiovascular mortality: possible causes and implications. Circ Res 2017;120:366–80.
[2] Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 2007;356:2388–98.
[3] Qu Y, Zhang F, Yang J, et al. Clinical characteristics and outcomes in Asian patients with premature coronary artery disease: insight from the FOCUS registry. Angiology 2019;70:354–60.
[4] Bauters C, Tricot O, Meurice T, et al. CORONOR Investigators.Long-term risk and predictors of cardiovascular death in stable coronary artery disease: the CORONOR study. Coron Artery Dis 2017;28:636–41.
[5] GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117–71.
[6] Levitan EB, Munter P, Chen L, et al. Burden of coronary heart disease rehospitalizations following acute myocardial infarction in older adults. Cardiovasc Drugs Ther 2016;30:323–31.
[7] World Health Organization. Global Health Observatory (GHO) data. Available at: http://www.who.int/gho/mortality_burden_disease/en/ [access October 28, 2020].
[8] The Writing Committee of the Report on Cardiovascular Health Diseases in China Report on cardiovascular health and diseases in China 2019: an updated summary. Chin J Evid Based Med 2020;20:313–34.
[9] Bomer C, Heesemann E, Saghalova V, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol 2017;5:423–30.
[10] Musunuru K, Qasim AN, Reilly MP. Genetics and Genomics of Atherosclerotic Cardiovascular Disease (M)Emergy and Rimon’s Principles and Practice of Medical Genetics and Genomics. Academic Press, 2020;209–230.
[11] Stewart J, Mannathan G, Wilkinson P. Primary prevention of cardiovascular disease: a review of contemporary guidance and literature. JRSM Cardiovasc Dis 2017;6:204800416768211.
[12] Evans A, Van Raal GC, McCarron P, et al. The genetics of coronary heart disease: the contribution of twin studies. Twin Res 2003;6:432–41.
[13] Knowles JW, Ashley EA. Cardiovascular disease: the rise of the genetic risk score. PLoS Med 2018;15:e1002546.
[14] Zhao X, Meng L, Jiang J, et al. Vascular endothelial growth factor gene polymorphisms and coronary heart disease: a systematic review and meta-analysis. Growth Factors 2018;36:153–63.
[15] Ma R, Zhu X, Yan B. SCARB1 rs3888 gene polymorphisms in coronary heart disease: a systematic review and a meta-analysis. Gene 2018;678:280–7.
[16] Hosseini DK, Atakia S, Hosseini HK, et al. Association of polymorphisms in ADAMTS-7 gene with the susceptibility to coronary artery disease - a systematic review and meta-analysis [published online ahead of print, 2020 Oct 29]. Aging (Albany NY) 2020;12:20915–23.
[17] Zeng TT, Tang DJ, Ye YX, et al. Influence of SCARB1 gene SNPs on serum lipid levels and susceptibility to coronary heart disease and cerebral infarction in a Chinese population. Gene 2017;626:319–25.
[18] Wang Y, Huang Q, Liu J, et al. Vascular endothelial growth factor A polymorphisms are associated with increased risk of coronary heart disease: a meta-analysis. Oncotarget 2017;8:30359–51.
[19] Wu DF, Yin RX, Cao XL, et al. MADD–FOLH1 polymorphisms and their haplotypes with serum lipid levels and the risk of coronary heart disease and ischemic stroke in a Chinese Han population. Nutrients 2016;8:208.
[20] Elfkai I, Mir R, Almutairi FM, et al. Cytochrome P450: polymorphisms and roles in cancer, diabetes and atherosclerosis. Asian Pac J Cancer Prev 2018;19:2057–70.
[21] Zhang JZ, Xie X, Ma YT, et al. Association between apolipoprotein C-III gene polymorphisms and coronary heart disease: a meta-analysis. Aging Dis 2016;7:36–44.
[22] Uehara S, Uno Y, Inoue T, et al. Novel marmoset cytochrome P450 4F2 in livers efficiently metabolizes human P450 2C9 and 2C19 substrates, S-warfarin, tolbutamide, Bufropropion, and omeprazole. Drug Metab Dispos 2015;43:1408–16.
[23] Lee SJ. Clinical application of CYP2C9 pharmacogenetics toward more personalized medicine. Front Genet 2015;3:318.
[24] Reynald RL, Sansen S, Stout CD, et al. Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19. J Biol Chem 2012;287:44581–91.
[25] Wang Y, Zhao X, Lin J, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 2016;316:70–8.
[26] Sofi F, Giusti B, Marcucci R, et al. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 2011;11:199–206.
[27] Zhang YY, Zhou X, Ji WJ, et al. Association between CYP2C19*2/*3 polymorphisms and coronary heart disease. Curr Med Sci 2019;39; 44–51.
[28] Ercan B, Ayaz L, Cøcek D, et al. Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem Funct 2008;26:309–13.
[29] Yang YN, Wang XL, Ma YT, et al. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease: the Uighur population. Clin Appl Thromb Hemost 2010;16:579–85.
[30] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Sys Rev 2015;4:1.
[31] David M, Alessandro L, Jennifer T, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
[32] Andreas S, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:63–5.
[33] Thakkinstian A, McElfühl P, D’Este C, et al. A method for meta-analysis of molecular association studies. Stat Med 2005;24:1291–306.
[34] Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of molecular association studies. Stat Med 2005;24:1291–306.
[35] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.
[36] Nichols M, Townsend N, Scarborough P, et al. Cardiovascular disease in Europe 2014: an epidemiological update. Eur Heart J 2014;35:2950–9.
[37] Poulter N. Coronary heart disease is a multifactorial disease. Am J Hypertens 1999;12(S6):925–5S.